Economy · News reference
Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14;
New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Phathom Pharmaceuticals, Inc. (PHAT)
Filed: 2026-09-29 AccNo: 0001193125-26-407696 Size: 144 KB Item 8.01: Other Events
Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first